< Back

'combination drug therapy'
Run an advanced search on this term

Search within:  

Sort results by:      



1-20 of 837   Next >
 
1.  
Dapagliflozin in combination therapy for treating type 2 diabetes. 2013 Jun. NGC:009946
National Institute for Health and Care Excellence (NICE) - National Government Agency [Non-U.S.]. View all guidelines by the developer(s)
2.  
Empagliflozin in combination therapy for treating type 2 diabetes. 2015 Mar. NGC:010695
National Institute for Health and Care Excellence (NICE) - National Government Agency [Non-U.S.]. View all guidelines by the developer(s)
4.  
Recommendations for drug therapies for relapsing-remitting multiple sclerosis. 2013 Oct. NGC:010418
Canadian Agency for Drugs and Technologies in Health - Nonprofit Organization. View all guidelines by the developer(s)
5.  
Exenatide prolonged-release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes. 2012 Feb. NGC:009078
National Institute for Health and Care Excellence (NICE) - National Government Agency [Non-U.S.]. View all guidelines by the developer(s)
6.  
Everolimus in combination with exemestane for treating advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy. 2013 Aug. NGC:010011
National Institute for Health and Care Excellence (NICE) - National Government Agency [Non-U.S.]. View all guidelines by the developer(s)
10.  
11.  
12.  
Interagency guideline on opioid dosing for chronic non-cancer pain: an educational aid to improve care and safety with opioid therapy. 2007 Mar (revised 2010 Jun). NGC:007902
Washington State Agency Medical Directors' Group - Independent Expert Panel. View all guidelines by the developer(s)
14.  
Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer. 2013 May. NGC:009893
National Institute for Health and Care Excellence (NICE) - National Government Agency [Non-U.S.]. View all guidelines by the developer(s)
15.  
Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia. 2015 Jun. NGC:010734
National Institute for Health and Care Excellence (NICE) - National Government Agency [Non-U.S.]. View all guidelines by the developer(s)
16.  
Optimal use recommendations for second- and third-line therapy for patients with type 2 diabetes. 2010 Aug (revised 2013 Jul). NGC:009997
Canadian Agency for Drugs and Technologies in Health - Nonprofit Organization. View all guidelines by the developer(s)
18.  
19.  
20.  
Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. 2008 (revised 2011). NGC:008788
World Health Organization - International Agency. View all guidelines by the developer(s)
1-20 of 837   Next >